GATA-3 as a Potential Therapeutic Target for Insulin Resistance and Type 2 Diabetes Mellitus

被引：13

作者：

Al-Jaber, Hend ^{[1
]}

Al-Mansoori, Layla ^{[1
]}

Elrayess, Mohamed A. ^{[1
]}

机构：

[1] Qatar Univ, Biomed Res Ctr, Doha, Qatar

来源：

CURRENT DIABETES REVIEWS | 2021年 / 17卷 / 02期

关键词：

GATA-3; therapeutic target; insulin resistance; adipogenesis; inflammation; type; 2; diabetes; TUMOR-NECROSIS-FACTOR; ADIPOSE-TISSUE INFLAMMATION; HUMAN SUBCUTANEOUS ADIPOGENESIS; REGULATORY T-CELLS; TRANSCRIPTION FACTORS; METABOLICALLY HEALTHY; FACTOR-ALPHA; INHIBITS ADIPOGENESIS; IMPAIRED ADIPOGENESIS; LINKING OBESITY;

D O I：

10.2174/1573399816666200705210417

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Impaired adipogenesis plays an important role in the development of obesity-associated insulin resistance and type 2 diabetes as it leads to ectopic fat deposition. The anti-adipogenic transcription factor GATA-3 was identified as one of the potential molecular targets responsible for the impairment of adipogenesis. The expression of GATA-3 is higher in insulinresistant obese individuals compared to BMI-matched insulin-sensitive counterparts. Adipose tissue inflammation is a crucial mediator of this process. Hyperglycemia mediates the activation of the immune system, partially through upregulation of GATA-3, causing exacerbation of the inflammatory state associated with obesity. This review discusses the evidence supporting the inhibition of GATA-3 as a useful therapeutic strategy in obesity-associated insulin resistance and type 2 diabetes, through up-regulation adipogenesis and amelioration of the immune response.

引用

页码：169 / 179

页数：11

共 50 条

[31] Role of insulin resistance in pathogenesis of diabetes mellitus type 2
Balabolkin, ML
Klebanova, EM
TERAPEVTICHESKII ARKHIV, 2003, 75 (01) : 72 - 77
[32] The role of mitochondria in insulin resistance and type 2 diabetes mellitus
Julia Szendroedi
Esther Phielix
Michael Roden
Nature Reviews Endocrinology, 2012, 8 : 92 - 103
[33] Mitochondrial Dysfunction, Insulin Resistance, and Type 2 Diabetes Mellitus
Abdul-Ghani, Muhammad A.
DeFronzo, Ralph A.
CURRENT DIABETES REPORTS, 2008, 8 (03) : 173 - 178
[34] Insulin resistance as the core defect in type 2 diabetes mellitus
Goldstein, BJ
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (5A): : 3G - 10G
[35] Potential Therapeutic Targets for the Management of Diabetes Mellitus Type 2
Prabhakar, Pranav Kumar
Batiha, Gaber El-Saber
CURRENT MEDICINAL CHEMISTRY, 2024, 31 (21) : 3167 - 3181
[36] Mitophagy: A potential therapeutic target for insulin resistance
Ning, Peng
Jiang, Xiaobo
Yang, Jing
Zhang, Jiaxing
Yang, Fan
Cao, Hongyi
FRONTIERS IN PHYSIOLOGY, 2022, 13
[37] Therapeutic Potential of miRNAs for Type 2 Diabetes Mellitus: An Overview
Palihaderu, P. A. D. S.
Mendis, B. I. L. M.
Premarathne, J. M. K. J. K.
Dias, W. K. R. R.
Yeap, Swee Keong
Ho, Wan Yong
Dissanayake, A. S.
Rajapakse, I. H.
Karunanayake, P.
Senarath, U.
Satharasinghe, D. A.
EPIGENETICS INSIGHTS, 2022, 15
[38] Insulin resistance in type 1 diabetes mellitus
Kaul, Kirti
Apostolopoulou, Maria
Roden, Michael
METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (12): : 1629 - 1639
[39] DIABETES MELLITUS ASSOCIATED WITH TYPE A INSULIN RESISTANCE
Sechko, Elena A.
Kuraeva, Tamara L.
Peterkova, Valentina A.
Laptev, Dmitry N.
DIABETES MELLITUS, 2023, 26 (03): : 284 - 290
[40] Focus on insulin resistance in type 2 diabetes: Therapeutic implications
Reusch, JEB
DIABETES EDUCATOR, 1998, 24 (02): : 188 - 193

← 1 2 3 4 5 →